180 related articles for article (PubMed ID: 35318110)
21. A Mitophagy-Related Gene Signature for Subtype Identification and Prognosis Prediction of Hepatocellular Carcinoma.
Liu C; Wu Z; Wang L; Yang Q; Huang J; Huang J
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36292980
[TBL] [Abstract][Full Text] [Related]
22. Construction and Validation of a Prognostic Gene-Based Model for Overall Survival Prediction in Hepatocellular Carcinoma Using an Integrated Statistical and Bioinformatic Approach.
Dessie EY; Tu SJ; Chiang HS; Tsai JJP; Chang YS; Chang JG; Ng KL
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562824
[TBL] [Abstract][Full Text] [Related]
23. LPCAT1 acts as an independent prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma.
Li L; Wang X; Ding Y; Hui N; Su B; Yang M
Eur J Med Res; 2022 Oct; 27(1):216. PubMed ID: 36307879
[TBL] [Abstract][Full Text] [Related]
24. Identification of a glycolysis-related gene signature for predicting prognosis in patients with hepatocellular carcinoma.
Kong J; Yu G; Si W; Li G; Chai J; Liu Y; Liu J
BMC Cancer; 2022 Feb; 22(1):142. PubMed ID: 35123420
[TBL] [Abstract][Full Text] [Related]
25. Hydroxysteroid 17-Beta Dehydrogenase 6 Is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma.
Wu M; Jiang L
Dig Dis Sci; 2022 Jan; 67(1):146-158. PubMed ID: 33495920
[TBL] [Abstract][Full Text] [Related]
26. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma.
Peng Y; Liu C; Li M; Li W; Zhang M; Jiang X; Chang Y; Liu L; Wang F; Zhao Q
Cancer Cell Int; 2021 Feb; 21(1):98. PubMed ID: 33568167
[TBL] [Abstract][Full Text] [Related]
27. Promising key genes associated with tumor microenvironments and prognosis of hepatocellular carcinoma.
Pan L; Fang J; Chen MY; Zhai ST; Zhang B; Jiang ZY; Juengpanich S; Wang YF; Cai XJ
World J Gastroenterol; 2020 Feb; 26(8):789-803. PubMed ID: 32148377
[TBL] [Abstract][Full Text] [Related]
28. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma.
Xu Q; Wang Y; Huang W
Int Immunopharmacol; 2021 Mar; 92():107333. PubMed ID: 33486322
[TBL] [Abstract][Full Text] [Related]
29. Immune-related microRNA signature for predicting prognosis and the immune microenvironment in hepatocellular carcinoma.
Li Y; He X; Zhang X; Xu Y; Wu Y; Xu X
Life Sci; 2021 Jan; 265():118799. PubMed ID: 33220285
[TBL] [Abstract][Full Text] [Related]
30. Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma.
Xu L; Zheng Q; Liu W
BMC Cancer; 2022 Mar; 22(1):229. PubMed ID: 35236323
[TBL] [Abstract][Full Text] [Related]
31. Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma.
Zhang G; Lv X; Yang Q; Liu H
BMC Cancer; 2022 Aug; 22(1):888. PubMed ID: 35964022
[TBL] [Abstract][Full Text] [Related]
32. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
Zhao QJ; Zhang J; Xu L; Liu FF
World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881
[TBL] [Abstract][Full Text] [Related]
33. Intra-tumor heterogeneity and prognostic risk signature for hepatocellular carcinoma based on single-cell analysis.
Liu C; Pu M; Ma Y; Wang C; Kong L; Zhang S; Zhao X; Lian X
Exp Biol Med (Maywood); 2022 Oct; 247(19):1741-1751. PubMed ID: 36330895
[TBL] [Abstract][Full Text] [Related]
34. PCNT is a prognostic biomarker correlated with tumor immune microenvironment in hepatocellular carcinoma and promotes tumor progression by inhibiting cell cycle arrest.
Wang X; Yang J; Luo L; Li X; Zhang Y
Aging (Albany NY); 2023 May; 15(10):4122-4143. PubMed ID: 37211383
[TBL] [Abstract][Full Text] [Related]
35. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma.
Wang X; He S; Zheng X; Huang S; Chen H; Chen H; Luo W; Guo Z; He X; Zhao Q
BMC Cancer; 2021 Sep; 21(1):1001. PubMed ID: 34493238
[TBL] [Abstract][Full Text] [Related]
36. Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma.
Wang J; Ling S; Ni J; Wan Y
BMC Cancer; 2022 Jun; 22(1):638. PubMed ID: 35681134
[TBL] [Abstract][Full Text] [Related]
37. Glycolysis-Related Gene Signature Can Predict Survival and Immune Status of Hepatocellular Carcinoma.
Xu Q; Miao D; Song X; Chen Z; Zeng L; Zhao L; Xu J; Lin Z; Yu F
Ann Surg Oncol; 2022 Jun; 29(6):3963-3976. PubMed ID: 35266081
[TBL] [Abstract][Full Text] [Related]
38. Regulatory T-cells-related signature for identifying a prognostic subtype of hepatocellular carcinoma with an exhausted tumor microenvironment.
Zhang G
Front Immunol; 2022; 13():975762. PubMed ID: 36189226
[TBL] [Abstract][Full Text] [Related]
39. Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma Patients.
Huang S; Zhang J; Lai X; Zhuang L; Wu J
Front Mol Biosci; 2021; 8():781307. PubMed ID: 35004851
[No Abstract] [Full Text] [Related]
40. A 4-gene prognostic signature predicting survival in hepatocellular carcinoma.
Chen PF; Li QH; Zeng LR; Yang XY; Peng PL; He JH; Fan B
J Cell Biochem; 2019 Jun; 120(6):9117-9124. PubMed ID: 30582205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
